Trade Show News

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Results at the first interim analysis of the trial showed KEYTRUDA significantly improved event-free survival (EFS) as pa...

SAN FRANCISCO--(BUSINESS WIRE)--Swimlane, AI hyperautomation for the entire security organization, today announced it has been named the “Most Valuable Pioneer” in AI maturity by QKS Group. In the 2025 QKS AI Maturity Matrix™, Swimlane ranks ahead of seven other vendors for its AI-first productization, advanced vision and agentic AI roadmap. Swimlane is ranked ahead of Palo Alto Networks, Cisco, D3, Tines, Fortinet, Torq and Anomali. “Swimlane is leading the shift toward a new AI-led model for...

ST. LOUIS--(BUSINESS WIRE)--EyeCare Partners will bring a strong lineup of clinical research and innovation to the upcoming annual ASCRS meeting....

NEW DELHI--(BUSINESS WIRE)--Resecurity, a U.S.-based cybersecurity company specializing in threat intelligence and digital risk management, successfully exhibited at MILIPOL India 2025, held from April 23–25 at India International Convention and Expo Centre (IICC), Dwarka, New Delhi. The event served as a premier meeting point for global leaders in homeland security, defense technology, and public safety. MILIPOL India is part of the prestigious MILIPOL network of homeland security exhibitions,...

ZURICH--(BUSINESS WIRE)--CDR-Life today announced the presentation of data for its novel T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations showcase the company's proprietary M-gager® platform-derived TCE candidates, with a focus on CDR404, currently in Phase 1 clinical trials for MAGE-A4-positive solid tumors. “The data presented at AACR highlight the potential advantages of our antibody-based approach to T cel...

TOKYO--(BUSINESS WIRE)--OKI Circuit Technology (“OTC”; President: Masaya Suzuki; Head office: Tsuruoka City, Yamagata), the OKI Group printed circuit board (PCB) company, has successfully developed 124-layer PCB technology for wafer inspection equipment designed for next-generation high bandwidth memory, such as HBM (Note 1) mounted on AI semiconductors. This is a roughly 15% increase in the number of layers over conventional 108-layer designs. OTC is seeking to establish mass production techno...

CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an abstract will be presented as a poster at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2025, taking place in Amsterdam, the Netherlands 7 – 10 May 2025. “We are excited to share preclinical data on our therapeutic vaccine candidate, CLB-4000, with the Hepatitis B communi...

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced new clinical data from its hypoxic ischemic encephalopathy (HIE) program, to be presented at the Pediatric Academic Societies (PAS) Annual Meeting, taking place April 24-28, 2025 in Honolulu, Hawaii. First Human Evidence of Predicted Inf...

GENEVA--(BUSINESS WIRE)--Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS...

CHICAGO--(BUSINESS WIRE)--Onc.AI, a digital health company developing advanced AI-driven clinical management solutions for oncology, today announced that findings from a recent collaboration with global biopharma company GSK using Onc.AI’s FDA breakthrough-designated Serial CTRS AI model will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The study externally evaluated Serial CTRS in GSK’s GARNET Phase I clinical trial (NCT02715284) Cohort E, that enrol...